Ardelyx Q2 net loss narrows 12.38% to $16.72 million; revenue climbs 31% year-over-year to $118.13 million
ARDX•Full-year guidance updated
For fiscal 2026, Ardelyx cut its IBSRELA revenue guidance to $350 million to $370 million.
The company reiterated XPHOZAH revenue guidance at $110 million to $120 million and said operating expenses are expected to be below $500 million.
Q2 revenue rises and net loss narrows
Ardelyx posted Q2 2026 total product revenue of $118.1 million, up 31% year over year.
Net loss narrowed to $16.7 million, or $0.07 per share, from a loss of $19.1 million, or $0.08.
- IBSRELA revenue rose 33% to $86.2 million.
- XPHOZAH revenue increased 27% to $31.9 million.
- R&D expense climbed to $26.1 million.
- SG&A expense increased to $101.4 million.
